Further Analysis Sample Clauses

Further Analysis. Debt to Asset Ratio is greater than or equal to .50 Does Not Meet Standard:  Upon further review following a preliminary Pending rating, the Commission concludes that there is financial risk such that heightened monitoring and/or intervention may be warranted. A Does Not Meet rating means that even based on more current financial information, the school is not currently meeting the standard or concerns previously identified, although not currently manifested, have been of a depth or duration that warrants continued attention.
Sample 1Sample 2Sample 3See All (60)
AutoNDA by SimpleDocs
Further Analysis. 🞏 Debt to Asset Ratio is greater than or equal to .50
Sample 1Sample 2Sample 3See All (7)
Further Analysis. 🞏 Enrollment Variance is below 95% in the most recent year Does Not Meet Target: 🞏 Upon further review following a preliminary Pending rating, the Commission concludes that there is financial risk such that heightened monitoring and/or intervention may be warranted. A Does Not Meet rating means that even based on more current financial information, the school is not currently meeting the target or concerns previously identified, although not currently manifested, have been of a depth or duration that warrants continued attention.
Sample 1Sample 2Sample 3See All (7)
Further Analysis. 🞏 Fund balance percentage is less than 25% Does Not Meet Target: 🞏 Upon further review following a preliminary Pending rating, the Commission concludes that there is financial risk such that heightened monitoring and/or intervention may be warranted. A Does Not Meet rating means that even based on more current financial information, the school is not currently meeting the target or concerns previously identified, although not currently manifested, have been of a depth or duration that warrants continued attention.
Sample 1Sample 2Sample 3See All (5)
Further Analysis. In this instance, if Xxxxx has some difficulties in concluding on the effectiveness of the treatment on the specific patient. He might want to consult his colleagues, the radiologist and another clinician, Xxxxx who are located elsewhere, to exchange ideas and collaboratively reach a decision. At present, there is no easy way to share data in real time for joint discussion.
Sample 1
Further Analysis. Energy temperature curve A suitable analytical tool is the Energy-Temperature curve (ET-curve). It could be constructed by registering the measured energy consumption and the average outdoor temperature for a certain period of time, for example once a week. The horizontal axis reflects the average ambient temperature for the week (GM / week) and the vertical axis the specific energy consumption of the heated area in the same week (kWh / m2 / week). Energy conusmption [kWh/m²week] Technical problem? Each building has its own unique ET-curve that shows what should be the energy consumption at different outside temperatures, in the case of proper operation of technical systems of the building. Lower and upper limit (eg  5%) can be set to the ET-curve of the building. Normal variations caused by solar radiation, wind, etc., fall within these limits. Deviations from ET-curve can report technical problem or deviation from the normal people’s behavior related to the energy consumption. This should be investigated and to take the necessary service activities.
Sample 1
Further Analysis. The Declaration aims to respond to the concerns expressed about the possible implications of the TRIPs Agreement for access to drugs. It does so in a number of ways. 230 WTO Agreements and public health.op.cit. 231 Xxxxx-Xxxxxx XXXXXXXXXX, Human Rights and the Law of the World Trade Organization *Journal of World Trade 37(2): 241–281, 2003. _ 2003 Kluwer Law International. 232 See WTO document WT/MIN (01)/DEC/W/2 of 14 November 2001, para. 4. First, it emphasizes that the TRIPs Agreement does not and should not prevent Members from taking measures to protect public health and reaffirms the right of Members to use, to the full, the provisions of the TRIPs Agreement which provide flexibility for this purpose. These important Declarations signal an acceptance by all WTO Members that they will not seek to prevent other Members from using these provisions.233 Second, the Declaration makes it clear that the TRIPs Agreement should be interpreted and implemented in a manner supportive of WTO Members' right to protect public health and, in particular, to promote access to medicines for all. Further, it highlights the importance of the objectives and principles of the TRIPs Agreement for the interpretation of its provisions. Although the Declaration does not refer specifically to Articles 7 and 8 of the TRIPs Agreement, entitled, respectively, "Objectives" and "Principles", it should be noted that developing country Members attach particular importance to these provisions. These statements thus provide important guidance to both individual Members and, in the event of disputes, WTO dispute settlement bodies. Third, the Declaration contains a number of important clarifications of some of the flexibilities contained in the TRIPs Agreement, while maintaining Members' commitments in the TRIPs Agreement. With regard to the least-developed country Members of the WTO, the Declaration accords them an extension of their transition period until the beginning of 2016 for the protection and enforcement of patents and rights in undisclosed information with respect to pharmaceutical products. Until then, these countries are exempt from these TRIPs obligations. And also, the TRIPs Council was mandated to find an expeditious solution to the problem of WTO Members with limited manufacturing capacities in making effective use of compulsory licencing and to report to the General Council before the end of 2002. It should also be noted that, while emphasizing the scope in the TRIPs Agre...
Sample 1
AutoNDA by SimpleDocs

Related to Further Analysis

  • Data Analysis In the meeting, the analysis that has led the College President to conclude that a reduction- in-force in the FSA at that College may be necessary will be shared. The analysis will include but is not limited to the following: ● Relationship of the FSA to the mission, vision, values, and strategic plan of the College and district ● External requirement for the services provided by the FSA such as accreditation or intergovernmental agreements ● Annual instructional load (as applicable) ● Percentage of annual instructional load taught by Residential Faculty (as applicable) ● Fall Full-Time Student Equivalent (FFTE) inclusive of dual enrollment ● Number of Residential Faculty teaching/working in the FSA ● Number of Residential Faculty whose primary FSA is the FSA being analyzed ● Revenue trends over five years for the FSA including but not limited to tuition and fees ● Expenditure trends over five years for the FSA including but not limited to personnel and capital ● Account balances for any fees accounts within the FSA ● Cost/benefit analysis of reducing all non-Residential Faculty plus one Residential Faculty within the FSA ● An explanation of the problem that reducing the number of faculty in the FSA would solve ● The list of potential Residential Faculty that are at risk of layoff as determined by the Vice Chancellor of Human Resources ● Other relevant information, as requested

  • Pending Further Analysis  Current Ratio is between 1.0 and 1.1 and one-year trend is negative or  Current Ratio is less than or equal to 1.0

  • Statistical Analysis 31 F-tests and t-tests will be used to analyze OV and Quality Acceptance data. The F-test is a 32 comparison of variances to determine if the OV and Quality Acceptance population variances 33 are equal. The t-test is a comparison of means to determine if the OV and Quality Acceptance 34 population means are equal. In addition to these two types of analyses, independent verification 35 and observation verification will also be used to validate the Quality Acceptance test results.

  • COMPENSATION ANALYSIS After the expiration of the second (2nd) Renewal Term of this Agreement, if any, a Compensation Analysis may be performed. At such time, based on the reported Total Gross Revenue, performance of the Concession, and/or Department’s existing rates for similarly- performing operations, Department may choose to increase the Concession Payment for the following Renewal Term(s), if any.

  • Analysis LICENSEE represents and agrees that it will only incorporate Components received from authorized suppliers into Licensed Products and for no other purpose, and that LICENSEE will not directly or indirectly attempt to reverse-engineer any material provided to it hereunder by LICENSEE or any supplier of any Component.

  • DATA COLLECTION AND ANALYSIS The goal of this task is to collect operational data from the project, to analyze that data for economic and environmental impacts, and to include the data and analysis in the Final Report. Formulas will be provided for calculations. A Final Report data collection template will be provided by the Energy Commission. The Recipient shall: • Develop data collection test plan. • Troubleshoot any issues identified. • Collect data, information, and analysis and develop a Final Report which includes: o Total gross project costs. o Length of time from award of bus(es) to project completion. o Fuel usage before and after the project.

  • Program Narrative All restricted xxxxxx courses which are taught for the purpose of qualifying an individual for restricted xxxxxx license to practice barbering shall consist of a minimum of 1200 hours of training to prepare each restricted xxxxxx to service their communities.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Analyses investigations, surveys and reports described in Section 5 above as Reimbursable Services;

  • Statistical Sampling Documentation a. A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO.

Time is Money Join Law Insider Premium to draft better contracts faster.